Medexus Drug Patent Portfolio
Medexus owns 2 orange book drugs protected by 2 US patents Given below is the list of Medexus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8664231 | Concentrated methotrexate solutions | 01 Jun, 2029 | Active |
| US7199162 | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation | 21 Mar, 2026 | Active |
Latest Legal Activities on Medexus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Medexus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US7199162 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Aug, 2025 | US8664231 (Litigated) |
| Second letter to regulating agency to determine regulatory review period | 09 Jul, 2025 | US7199162 |
| Letter from FDA or Dept of Agriculture re PTE application | 27 Jun, 2025 | US7199162 |
| Interim Patent Term Extension Granted | 20 Mar, 2025 | US7199162 |
| Initial letter Re: PTE Application to regulating agency | 13 Mar, 2025 | US7199162 |
| Patent Term Extension Application under 35 USC 156 Filed | 28 Feb, 2025 | US7199162 |
| PTE Interim Patent Extension filed | 28 Feb, 2025 | US7199162 |
| Interim Patent Term Extension Granted | 01 Oct, 2024 | US7199162 |
| Interim Patent Term Extension Granted | 30 Sep, 2022 | US7199162 |
| Interim Patent Term Extension Granted | 05 Oct, 2021 | US7199162 |
| Post Issue Communication - Certificate of Correction | 29 Sep, 2021 | US7199162 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Aug, 2021 | US8664231 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) | 15 Sep, 2020 | US7199162 |
| Email Notification | 15 Sep, 2020 | US7199162 |
Medexus's Drug Patent Litigations
Medexus's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 01, 2014, against patent number US8664231. The petitioner Antares Pharma, Inc., challenged the validity of this patent, with Medac Gesellschaft Fur Klinische as the respondent. Click below to track the latest information on how companies are challenging Medexus's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8664231 | July, 2016 |
Final Written Decision
(07 Feb, 2018)
| MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH et al. | Koios Pharmaceuticals LLC |
| US8664231 | February, 2016 |
Terminated-Settled
(08 Dec, 2016)
| MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH | Frontier Therapeutics, LLC |
| US8664231 | July, 2014 |
Terminated-Settled
(30 Apr, 2015)
| Medac Gesellschaft Fur Klinische | Antares Pharma, Inc. |
Medexus Drug Patents' Oppositions Filed in EPO
Medexus drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 15, 2011, by Antares Pharma, Inc.. This opposition was filed on patent number EP07786239A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP07786239A | Oct, 2012 | Actavis Group ehf | Opposition rejected |
| EP07786239A | Sep, 2011 | Antares Pharma, Inc. | Opposition rejected |
Medexus's Family Patents
Medexus Drug List
Given below is the complete list of Medexus's drugs and the patents protecting them.
1. Grafapex
Grafapex is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7199162 | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
21 Mar, 2026
(5 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Grafapex's drug page
2. Rasuvo
Rasuvo is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8664231 | Concentrated methotrexate solutions |
01 Jun, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rasuvo's drug page